Pharmacologic targeting of T helper (T H ) cell trafficking poses an attractive opportunity for amelioration of autoimmune diseases such as multiple sclerosis (MS). MS risk is associated with vitamin D deficiency, and its bioactive form, 1,25-dihydroxyvitamin D3 [1, 25(OH) ' s in vivo action remains incompletely understood. The pathogeneses of MS and EAE require localization of selfreactive T cells to the CNS. Myelin-specific effector T cells are primed in the lymph nodes (LNs) and subsequently travel a complex route and arrive at the CNS barriers. There, a sequential interaction with a multitude of endothelial adhesion molecules and chemokines leads to T helper (T H ) cell migration into the CNS parenchyma. Several ligand/receptor pairs have been implicated in the pathogeneses of MS and EAE (5, 6). Therefore, manipulation of molecules involved in T-cell trafficking poses an attractive opportunity for therapeutic interventions. Recent studies have highlighted a role for vitamin D in immune cell migration (7-10), but whether 1,25(OH) 2 D 3 affects trafficking of lymphocytes in MS and/or EAE has not been investigated.
Pharmacologic targeting of T helper (T H ) cell trafficking poses an attractive opportunity for amelioration of autoimmune diseases such as multiple sclerosis (MS). MS risk is associated with vitamin D deficiency, and its bioactive form, 1,25-dihydroxyvitamin D3 [1, 25(OH) 2 D 3 ], has been shown to prevent experimental autoimmune encephalomyelitis, a mouse model of MS, via an incompletely understood mechanism. Herein, we systematically examined 1,25 (OH) 2 D 3 effects on T H cells during their migration from the lymph nodes to the CNS. Our data demonstrate that myelin-reactive T H cells are successfully generated in the presence of 1,25(OH) 2 D 3 , secrete proinflammatory cytokines, and do not preferentially differentiate into suppressor T cells. These cells are able to leave the lymph node, enter the peripheral circulation, and migrate to the s. c. immunization sites. However, T H cells from 1,25(OH) 2 D 3 -treated mice are unable to enter the CNS parenchyma but are instead maintained in the periphery. Upon treatment cessation, mice rapidly develop experimental autoimmune encephalomyelitis, demonstrating that 1,25(OH) 2 D 3 prevents the disease only temporarily likely by halting T H cell migration into the CNS.
M ultiple sclerosis (MS) is an immune-mediated demyelinating disorder of the central nervous system (CNS). Whereas its etiology is unknown, a number of environmental and genetic factors contribute to the risk of developing MS (1).
Epidemiologic studies demonstrate a strong correlation between MS risk and vitamin D deficiency (2) . Higher levels of circulating 25-hydroxyvitamin D 3 have been recently shown to correlate with a reduction in the number of new T2 and gadoliniumenhancing lesions (3) . Moreover, the bioactive form of vitamin D, 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ], can completely prevent and treat established experimental autoimmune encephalomyelitis (EAE) (4) , a murine MS model. Nonetheless, the mechanism of 1,25(OH) 2 D 3 ' s in vivo action remains incompletely understood. The pathogeneses of MS and EAE require localization of selfreactive T cells to the CNS. Myelin-specific effector T cells are primed in the lymph nodes (LNs) and subsequently travel a complex route and arrive at the CNS barriers. There, a sequential interaction with a multitude of endothelial adhesion molecules and chemokines leads to T helper (T H ) cell migration into the CNS parenchyma. Several ligand/receptor pairs have been implicated in the pathogeneses of MS and EAE (5, 6) . Therefore, manipulation of molecules involved in T-cell trafficking poses an attractive opportunity for therapeutic interventions. Recent studies have highlighted a role for vitamin D in immune cell migration (7) (8) (9) (10) , but whether 1,25(OH) 2 D 3 affects trafficking of lymphocytes in MS and/or EAE has not been investigated.
A recent study using conditional deletion of the vitamin D receptor (VDR) has demonstrated that 1,25(OH) 2 D 3 prevents EAE by acting directly on the encephalitogenic T H cells (11) . We hypothesized that 1,25(OH) 2 Significance Vitamin D plays an important role in regulating the immune system in health and disease and may be beneficial for patients with multiple sclerosis. It prevents CNS autoimmunity in mice by an incompletely understood mechanism. The present study is a systematic evaluation of the vitamin D effects on T lymphocytes at each step of their journey to the CNS. The data demonstrate that vitamin D does not affect generation of pathogenic cells but prevents their presence in the CNS. Unlike current long-acting drugs that impair immune cell trafficking, the effect of vitamin D is quickly reversed after treatment cessation, which could prove advantageous when immune function needs to be reestablished in the setting of infection.
antibodies and exhibited equivalent MOG-specific proliferative capacity. Moreover, 1,25(OH) 2 (Fig. S4B ). An ex vivo suppression assay demonstrated no significant differences between the effects of T H cells from vehicle-and 1,25(OH) 2 D 3 -treated animals on proliferation of naive responder cells (Fig. S4C) 2 D 3 , or the immunomodulatory drug FTY720 which sequesters lymphocytes in lymph nodes. Expansion of MOG-specific cells in the dLNs was equivalent in the three treatment groups compared with the CFA-only control ( Fig. 2A) . Whereas equivalent proportions of MOG-specific T H cells were observed in the spleen and peripheral circulation of 1,25(OH) 2 D 3 -and vehicle-treated mice, FTY720 treatment, as expected (15) , led to a significant reduction of 2D2 cells in these compartments and to lymphopenia ( Fig. 2 A and B) . Furthermore, leuko-and lymphocytosis were observed 8 d after immunization and before disease onset in both vehicle-and 1,25(OH) 2 D 3 -treated mice compared with day 0 (Fig. 2C ). After clinical symptoms had developed in the vehicle-but not in 1,25(OH) 2 D 3 -treated animals (day 16), blood counts remained elevated in the 1,25(OH) 2 D 3 group but returned almost to baseline in the vehicle-treated animals, suggesting that, whereas encephalitogenic cells migrate into the CNS in the vehicle group, the cells remain in the circulation in the 1,25(OH) 2 D 3 -treated mice. During the chronic stage of disease (day 22), blood counts returned to baseline in both groups, illustrating the contraction phase of the immune response. In vitro restimulation of splenocytes and LN cells isolated at the peak of disease revealed that splenocytes from the 1,25(OH) 2 D 3 -treated animals secreted significantly higher levels of IFNγ and IL-17 than the cells from the vehicle group, indicating paucity of MOGreactive T H cells in the spleens of vehicle-but not 1,25(OH) 2 D 3 -treated mice (Fig. 2D) . Cells from all groups demonstrated an appropriate polyclonal response to anti-CD3/CD28 stimulation. These findings indicate that MOG-specific T H cells migrate into the CNS in vehicle-treated animals to cause EAE but remain in the periphery in the 1,25(OH) 2 were transferred into the B6(Cg)-Tyr c-2J /J strain of mice a day before immunization. Increased signal was observed in the dLNs 3 d postimmunization, after which a dramatic increase in the signal was detected at the immunization sites, suggesting that 2D2-Luc T H cells expand within the dLNs and then migrate to and accumulate in the nonlymphoid injection sites (Fig. 3) . After signal intensity at the injection site peaked around day 9, with minimal signal observed elsewhere, the signal gradually decreased to baseline. Because significant signal was not observed outside the dLNs and sites of immunization, the decline in signal after day 10 can be best explained by cell loss during the contraction phase of the immune response rather than the redistribution of 2D2-Luc cells to other tissues such as the CNS. The signal intensity approached the preimmunization levels by the time the vehicle-treated animals developed clinically apparent disease (day 14) , suggesting that the endogenous Luc-negative MOG-reactive T H cells were the cells causing the disease. Importantly, no difference in the signal intensity and distribution was observed between the vehicle-and 1,25(OH) 2 D 3 -treated animals, indicating that 1,25(OH) 2 D 3 does not affect expansion of MOG-specific T H cells or their migration to the site of immunization. These data further confirm that 1,25(OH) 2 D 3 does not affect generation of MOG-specific T H cells, which are not confined to the lymphoid organs but are able to enter nonlymphoid injection sites.
1,25(OH) 2 D 3 -Treated Mice
Have Intact Blood-CNS Barrier. The apparent inhibition of transmigration of T H cells into the CNS parenchyma could occur at the level of the blood-brain barrier (BBB). Evaluation of Evans Blue dye extravasation at the peak of EAE revealed an intact BBB of the 1,25(OH) 2 D 3 -treated mice, whereas the paralyzed vehicle-treated mice exhibited significant loss of BBB integrity (Fig. S5A) . Moreover, IgG extravasated into the CNS parenchyma in the vehicle-but not 1,25 (OH) 2 D 3 -treated mice (Fig. S5B ). Although these findings suggest a potential direct effect of 1,25(OH) 2 D 3 on the BBB endothelium, an intrinsic inability of encephalitogenic T cells to enter the CNS would also leave the BBB intact. Hence, these findings maintain that 1,25(OH) 2 D 3 prevents T H cells' migration into the CNS and argue against the possibility that the pathogenic T H cells transiently enter the CNS parenchyma and rapidly recirculate through cervical lymphatics or undergo apoptosis in the CNS, as this would undermine BBB integrity. To migrate into the CNS parenchyma, encephalitogenic T H cells must cross the BBB or bloodleptomeningeal barrier (BLMB) and the glia limitans (16) . Cell sequestration within the perivascular or leptomeningeal space prevents clinical disease (17, 18) . Before the onset of the clinical symptoms, inflammatory infiltrates were contained within the leptomeningeal space in approximately half of the vehicle-treated mice, whereas no infiltrates were detected in any of 1,25(OH) 2 D 3 -treated or naive mice (Fig. S6A) . At the peak of disease, infiltrates were observed within the spinal cord parenchyma of all vehicletreated controls, whereas no meningeal or parenchymal infiltrates were detected in the 1,25(OH) 2 D 3 -treated or naive mice (Fig. S6B) . Moreover, vehicle-but not 1,25(OH) 2 D 3 -treated mice exhibited abundant perivascular cuffing within the spinal cord at the peak of disease (Fig. S6C) . T-cell infiltration was further examined by CD3 staining (Fig. S7) (Fig. 4A) . Equivalent proportions of splenic T H cells in vehicle-treated and withdrawal mice were CD44 hi CD62L low and produced IFNγ and IL-17 ( Fig. S8 A and B) . In addition, the immune response has contracted by the time withdrawal mice developed the disease, as indicated by return of leukocyte and lymphocyte counts to baseline (Fig. S8C) and undetectable IFNγ and IL-17 secretion in response to in vitro restimulation with MOG. Interestingly, whereas the proportions of T H cells in the CNS were comparable between the two groups, the proportion of CD8 + T cells was significantly lower in the withdrawal animals (Fig. 4B) (Fig. 5A) . However, no change in the expression of α4-integrin (CD49d) or the chemokine receptor CCR6, receptors involved in T H cell CNS migration (19, 20) , was detected on splenic T H cells of vehicleor 1,25(OH) 2 D 3 -treated animals at the examined time point (Fig.  S9) . Importantly, after cessation of the 1,25(OH) 2 D 3 treatment, the proportion of CXCR3
+ T H cells reached that of the vehicletreated animals (Fig. 5B) . These findings suggest that 1,25 (OH) 2 D 3 may prevent T H cell extravasation across the BBB endothelium by regulating chemokine receptor expression, and that the effect of 1,25(OH) 2 D 3 is easily reversible, as CXCR3 expression is rapidly turned over in the absence of treatment.
Discussion
To induce an organ-specific autoimmune response, self-reactive T cells must migrate to their target tissues, a process that is regulated by chemokines and their cognate receptors, selectins, integrins, and metalloproteinases. Pharmacologic targeting of T H cell migration poses an attractive opportunity for amelioration of immune-mediated diseases such as MS. The data presented herein provide unique evidence that 1,25(OH) 2 21) ; however, the mechanism of its in vivo action has not been fully elucidated and may differ for prevention and treatment paradigms. A recent study using conditional deletion of VDR demonstrated that 1,25(OH) 2 D 3 prevents EAE by acting directly on the encephalitogenic T H cells (11) . 1,25(OH) 2 D 3 has been shown to inhibit T-cell proliferation and IL-17 and IFNγ production in in vitro studies (7, 22) , and it has been suggested that 1,25(OH) 2 D 3 prevents EAE by inhibiting the differentiation and function of the pathogenic T H 1 and T H 17 cells (7, 14) . However, in our prevention paradigm, 1,25(OH) 2 -effector cells exhibit abundant expression. In agreement with these observations, we detected no changes in the proportion of total or MOG-specific Tregs or in the suppressive capacity of T H cells from 1,25(OH) 2 D 3 -treated animals. Although it is possible that 1,25(OH) 2 D 3 exerted undetected immunoregulatory effects, one would expect this to be long lasting. Tregs have been shown to lose regulatory activity and acquire a proinflammatory phenotype under certain conditions (23); however, the majority of Tregs are considered to be phenotypically stable (24) . Thus, the rapid EAE onset observed The complex route of encephalitogenic T H cells from the LNs to the CNS is only partially defined. With the use of in vivo bioluminescent imaging, we demonstrate that migration to the s.c. immunization sites is an important step in T H cell journey to the CNS and is unaffected by 1,25(OH) 2 D 3 . However, the functional significance of this localization for EAE induction remains to be elucidated. Interestingly, no bioluminescent signal was detected in the CNS in either treatment group, and the total body signal intensity approached the preimmunization levels by the time clinical symptoms were apparent, indicating that the 2D2-Luc cell population contracted by the onset of disease. This finding suggests that the endogenous T H cells were the EAEinducing cells. Low avidity for the MHC-MOG complex could allow 2D2 cells to be outcompeted by the endogenous MOGspecific T H cells over time, leading to their contracture before the onset of disease (25) . Alternatively, this imaging modality might not be capable of detecting the few 2D2-Luc cells that do arrive in the CNS. Overall, the imaging data established that 1,25 (OH) 2 D 3 does not affect the ability of the MOG-specific T H cells to migrate to the immunization sites, whereas FACS and immunohistochemical approaches demonstrate that T H cells are not sequestered in the perivascular/leptomeningeal space, suggesting that 1,25(OH) 2 D 3 prevents T cells from crossing the CNS endothelium and thus maintains them in the periphery. Taken together, these findings emphasize a potential difference between migration of T H cells to the s.c. injection sites versus the CNS, indicating that 1,25(OH) 2 D 3 might be selectively modulating the CNS-tropic T H cell migration.
Although much progress has been made in understanding Tcell trafficking to the CNS (6, 16) , the molecular signature that permits myelin-reactive T H cells to breach the CNS barriers and infiltrate the parenchyma remains to be fully defined. Chemokine receptor expression profiles differ by T H cell subtype and, in combination with selectins and integrins, define their final destination (26, 27) . Chemokine receptors are dynamic G proteincoupled receptors, and their expression on T H cells is regulated by T cell receptor (TCR) stimulation, cytokines, vitamins, and other mediators present at the time of priming (28). 1,25(OH) 2 D 3 has been previously shown to modulate the expression of several chemokine receptors on both mouse and human T H cells in vitro (7, 10 Whereas no changes in α4-integrin expression were detected in 1,25(OH) 2 D 3 -treated mice, the integrin conformation was not examined. G protein-coupled chemokine receptor signaling leads to integrin activation; hence, changes in chemokine receptor expression could potentially impair interactions between T-cell integrins and their endothelial ligands, inhibiting stable adhesion of T cells to the CNS endothelium. Furthermore, although 1,25(OH) 2 D 3 has been shown to reduce expression of CCR6 and to inhibit trafficking of T H 17 cells toward the chemokine CCL20 in vitro (7), the role of CCR6 in EAE induction is controversial. CCR6 deletion has been shown to prevent T H 17 cell CNS entry through the choroid plexus, thus inhibiting EAE (19) , but contradictory studies have undermined this observation (36, 37) . Whereas the molecular signature that defines encephalitogenic T H cells is not fully characterized, our findings suggest that the presence of 1,25(OH) 2 D 3 during the priming of MOGspecific T H cells can alter their expression of chemokine receptors without affecting differentiation, thus potentially reversibly modulating T H cell trafficking phenotype and ameliorating EAE. The reversal of 1,25(OH) 2 D 3 effects could prove advantageous when immune function needs to be reestablished during an infection. However, this rapid rebound effect raises concern about the use of vitamin D for MS treatment. If vitamin D supplementation sequesters the pathogenic T cells in the periphery, treatment cessation could potentially release these cells into the CNS and lead to a clinical relapse. Overall, the present study expands the understanding of the mechanism by which 1,25 (OH) 2 D 3 prevents EAE and emphasizes the importance of understanding the molecular mechanisms underlying the extravasation of encephalitogenic T cells into the CNS, as well as its prevention, in advancing the treatment for diseases caused by CNS inflammation such as MS.
Methods
Additional methods can be found in SI Methods.
Mice. C57BL/6 and CD45.1 + congenic mice were purchased from the National Cancer Institute. B6(Cg)-Tyr c-2J
/J mice and 2D2 mice (TCR-transgenic specific for MOG 35-55) were purchased from The Jackson Laboratory. Luc mice were a kind gift from Robert Negrin (Stanford University, Stanford, CA). Luc mice expressing MOG-specific TCR (2D2-Luc) were generated and bred in our facility. All mice were maintained in a federally approved animal facility at Johns Hopkins University in accordance with the Institutional Animal Care and Use Committee. Female mice of 8-12 wk of age were used in all of the experiments.
Induction of EAE and Treatment. MOG EAE was induced and monitored as previously described (38 Cell Isolation and Culture. Single-cell suspensions were made by passing spleens and lymph nodes through a 70-μm nylon cell strainer (BD Biosciences). Splenic T H cells were isolated using EasySep Mouse CD4 + T-cell Enrichment kit (Stemcell Technologies), following the manufacturer's protocol. Mononuclear cells were isolated from the CNS using a 70-30% Percoll step gradient as previously described (39) . Cells were cultured in RPMI 1640 supplemented with 10% vol/vol FBS, 100 μg/mL penicillin and streptomycin, 0.5 μM 2-mercaptoethanol, 10 mM Hepes buffer, 1 mM sodium pyruvate, and MEM Nonessential amino acids.
ELISA. Spleen and dLN cells were cultured in complete RPMI medium 1640 (5 × 10 6 cells per well in 24-well plates) in the presence of 0 or 10 μg/mL MOG 35-55, or 0.5 μg/mL anti-CD3 and anti-CD28 antibodies (BD Biosciences). Supernatants were collected after 72 h, and the levels of IFNγ and IL-17 were quantified using ELISA kits according to manufacturer's instructions (BioLegend).
Flow Cytometry. Surface antigens were stained with anti-CD4 (BD Biosciences; RM4-5), anti-CD8 (BD Biosciences; 53-6.7), anti-CD45.2 (BD Biosciences; 104), and anti-CXCR3 (eBioscience; CXCR3-173). Flow cytometric analyses were performed on a FACSCalibur instrument (BD Biosciences) and the results were analyzed using FlowJo software (TreeStar).
Complete Blood Counts. Absolute counts of white blood cells and lymphocytes in peripheral blood were obtained using Drew Scientific Hemavet 950FS (Drew Scientific).
In Vivo Bioluminescent Imaging. B6(Cg)-Tyr c-2J
/J mice were used as recipients because white coats minimize light absorption. Treatment with vehicle or 1,25(OH) 2 D 3 was started on the day of transfer of 2D2-Luc T H cells, and EAE was induced the following day. Mice were anesthetized with isoflurane, and images were obtained 8 min after i.p. injections of D-luciferin (150 mg/kg body weight; Regis Technologies) with a CCD camera cooled to −180°C, using the IVIS Spectrum Imaging system (Xenogen) with the field of view set at subject height (1.2 cm). The photographic images were obtained using a 0.2-s exposure, 8f/stop, and small binning. The bioluminescent images were obtained using 300-s exposures, 1f/stop, medium binning, and an open filter. The bioluminescent and gray-scale images were overlaid using Living Image software (Xenogen). Regions of interest were drawn around entire animals, and the total flux (p/s) per region of interest was obtained.
Statistical Analysis. Statistical analysis was conducted using GraphPad Prism software (GraphPad). Mann-Whitney test was used to compare data from noninterval scales. Two-tailed Student t test was used to analyze normally distributed data. Results were considered significant if the P value was <0.05: *P < 0.05, **P < 0.01, ***P < 0.001; NS, no significant difference. All error bars represent SEM.
